200 results
Page 5 of 10
8-K
EX-99.1
8mpm7u5vtk
27 Apr 20
Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting
4:31pm
8-K
EX-99.1
h9ou0z471uga
14 Apr 20
Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting
12:00am
8-K
EX-99.1
znpg6
6 Mar 20
Bio-path Holdings Reports Full Year 2019 Financial Results
7:10am
8-K
EX-99.1
3315m
8 Jan 20
Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
4:30pm
8-K
9gin0lxbwqcq3w pj0ub
26 Nov 19
Bio-path Holdings Announces Successful Completion of Safety Testing In Stage 2 of Phase 2 Clinical Trial In Acute Myeloid Leukemia
4:30pm
8-K
EX-99.1
2f0v94lvuir
26 Nov 19
Bio-path Holdings Announces Successful Completion of Safety Testing In Stage 2 of Phase 2 Clinical Trial In Acute Myeloid Leukemia
4:30pm
424B5
3672xq3 zx5lhbmc5
22 Nov 19
Prospectus supplement for primary offering
7:41pm
8-K
EX-10.1
wlxwplqp m3gd8xc7q
22 Nov 19
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-99.1
jzaqgx3oh3ub5uu
21 Nov 19
Bio-path Holdings Announces Clearance of Investigational New Drug Application for BP1002
8:20am
8-K
EX-99.1
yd1zodlnsdb
15 Nov 19
Bio-path Holdings Reports Third Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
8nolf7n5aey
26 Aug 19
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
9:33pm
8-K
EX-99.1
lda7dxc6
15 Aug 19
Bio-path Holdings Reports Second Quarter 2019 Financial Results
7:05am
424B5
xe63xhbtq5l dp2
6 Jun 19
Prospectus supplement for primary offering
5:06pm
424B5
8q5nyov1oaiwr8dw
6 Jun 19
Prospectus supplement for primary offering
5:03pm